Atea Pharmaceuticals, Inc.
AVIRHealthcareNASDAQBiotechnology · Last scanned Oct 26, 2026
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Atea Pharmaceuticals, Inc. focuses on Biotechnology services and products. Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. At a $324.0M market cap, Atea Pharmaceuticals, Inc. ranks as a small-cap company within healthcare. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV).
Market Cap
$324.0M
Beta
0.39
P/E (TTM)
—
P/E (Fwd)
-2.73
EPS (TTM)
$-2.09
EPS (Fwd)
$-1.48
ROE
-58.1%
ROA
-36.7%
Cash
$219.5M
Total Debt
$424,000
Free CF
-$92.8M
52W Change
24.3%
Annual Financials
Cash vs Debt
Where AVIR stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, AVIR finished 13.41% below its 150-day moving average ($5.07) and 10.41% below its 200-day moving average ($4.90). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is AVIR overbought or oversold?
At the October 20, 2026 close, AVIR's RSI(14) was 20.5, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Atea Pharmaceuticals, Inc. holds $219.5M in cash against $424K in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow is running at -$92.8M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -58.1%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
AVIR's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. With cash comfortably exceeding debt, AVIR has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Atea Pharmaceuticals, Inc.'s trajectory.